{"url_path":"/sec/plse/8-k/2026-04-27/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1625101/0001437749-26-013383-index.html","accession_number":"0001437749-26-013383","cik":"0001625101","ticker":"PLSE","issuer_name":"PULSE BIOSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1625101/0001437749-26-013383-index.html","primary_entity_key":"0001625101","primary_entity_name":"PULSE BIOSCIENCES, INC."},"word_count":496,"has_tables":true,"body_markdown":"**Item 7.01**\n\n**Regulation FD Disclosure.**\n\n \n\nOn April 25, 2026, Pulse Biosciences, Inc. (the “Company”) issued a press release announcing additional key findings from the first-in-human clinical study of its nPulse Cardiac Catheter System to treat atrial fibrillation (the “study”). The findings were presented at Heart Rhythm 2026 in Chicago, Illinois, by Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital. Key findings from the study include:\n\n \n\n \n●\n\nSustained 100% procedural success of evaluable patients by holter at 6 months (95/95);\n\n \n●\n\nSustained 96% procedural success of evaluable patients by holter at one year (51/53);\n\n \n●\n\nSustained 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year;\n\n \n●\n\nConsistently efficient procedural performance, including:\n\n \n \n\n        Left atrial dwell time: 18.6 ± 13.0 minutes;\n\n \n \n\n        Total procedure time: 60.2 ± 27.7 minutes;\n\n \n \n\n        Fluoroscopy time: 9.4 ± 5.9 minutes;\n\n \n \n\n        Average applications per-patient for PVI: 12.3 ± 2.6; and\n\n \n●\n\nSafety profile across total cohort: maintained low serious adverse event rate, with 1.7% (3/177) of subjects experiencing a SAE related to the primary safety endpoint.\n\n \n\nA copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\n\n \n\nOn April 25, 2026, the Company also posted an updated investor presentation on its website (“Investor Deck”). This updated investor presentation discloses, among other things, some of the key findings from the study. The Company has used this updated Investor Deck and expects to continue to use it, either in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. A copy of the Investor Deck is attached hereto as Exhibit 99.2 and incorporated by reference in this Item 7.01. The Investor Deck is also available on the Company’s website at www.pulsebiosciences.com under “Investors.”\n\n \n\nExcept for the Investor Deck, information contained on, or accessible through, the Company’s website is not a part of, and is not incorporated by reference in, this Current Report on Form 8-K. The information contained in the Investor Deck itself is summary information only and it contains forward looking statements that are subject to risks and uncertainties, including those set forth in the Company’s filings with the U.S. Securities and Exchange Commission. Also, the information in the Investor Deck is as of April 2026, and the Company undertakes no obligation to publicly update or revise the information contained in the Investor Deck or this Item 7.01, except as required by law, although it made do so from time to time.\n\n \n\n*The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed*“*filed*”*for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the*“*Exchange Act*”*), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly stated otherwise.*"}